RecruitingNCT05397132

Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies

Mechanisms of Disease Relapse/Resistance in CAR T Therapy for Hematologic Malignancies

Sponsor

Duke University

Enrollment

50 participants

Start Date

May 27, 2022

Study Type

OBSERVATIONAL

Conditions

Hematologic Malignancy

Summary

The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistance in CAR T therapy.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.
Has a confirmed diagnosis of hematologic malignancy and will be undergoing CAR T therapy with commercial CAR T product.
Patient who has a confirmed diagnosis of hematologic malignancy and will be receiving CAR T therapy under clinical trial protocol will also be eligible if the clinical trial sponsor and the investigator approve patient participation in the study.